Clinicians often face significant hurdles when treating patients with treatment-resistant schizophrenia (TRS) who refuse oral intake. Specifically, **intramuscular clozapine for schizophrenia** serves as a vital clinical bridge for those requiring rapid stabilization. This systematic scoping review evaluates the feasibility and safety of using the injectable formulation. Furthermore, the review highlights how medical teams utilize this route to re-establish oral therapy. Consequently, psychiatrists can manage acute psychotic symptoms more effectively while adhering to safety guidelines.

Feasibility and Clinical Governance

The results demonstrate that intramuscular clozapine is feasible within settings that have robust pharmacy support. Most protocols focus on using the injection as a time-limited intervention. Additionally, services describe the transition to oral medication as occurring rapidly, often within a few days. Because patients often regain insight after stabilization, the use of coercive measures typically decreases over time. Moreover, the study confirms that IMI clozapine helps maintain the continuity of care for those who would otherwise fail therapy.

Clinical Use of Intramuscular clozapine for schizophrenia

Safety profiles for the intramuscular route align closely with known oral clozapine data. However, route-specific adverse effects like localized pain or swelling occur more frequently. Similarly, clinicians infrequently reported serious systemic events across the analyzed case literature. Therefore, clinical monitoring should focus on both the site of injection and systemic tolerability. Furthermore, standardized dosing conversion tables remain essential for pharmacy teams to minimize medication errors. Consequently, these findings support the use of IMI clozapine as a practical solution for oral refusal.

Looking Ahead

Ultimately, more prospective studies are necessary to define standardized procedures and long-term outcomes. Although current data primarily comes from case reports, the evidence suggests a positive role for this intervention. In addition, future research should incorporate patient-centered outcomes to better understand the subjective experience. Therefore, hospitals should develop clear policies to guide the safe implementation of this bridging strategy.

What is the primary role of intramuscular clozapine?

Psychiatrists use intramuscular clozapine as a short-term bridge to facilitate the transition to oral medication in patients who refuse oral intake during acute psychosis.

Are there specific side effects associated with the injection?

Yes, patients may experience localized pain, redness, or nodules at the injection site, though systemic safety mirrors that of oral clozapine.

Is intramuscular clozapine commonly used in India?

While oral clozapine remains the gold standard in India, the intramuscular formulation provides a feasibility-tested method for overcoming medication refusal in TRS.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional physician-patient relationship. Always seek the advice of a qualified healthcare provider for medical conditions. Refer to the latest local and national guidelines for clinical practice.

References

Dhaliwal N et al. Intramuscular Clozapine: A Systematic Scoping Review of Clinical Feasibility, Safety, and Efficacy. J Clin Psychopharmacol. 2026 May 25. doi: 10.1097/JCP.0000000000002198. PMID: 42186904.

Ho K et al. Rechallenging Clozapine via Intramuscular Route in Treatment-Resistant Schizophrenia Post-Small Bowel Obstruction: A Case Report. Medicines Management. 2024.

Taylor D et al. The Maudsley Prescribing Guidelines in Psychiatry. 14th ed. Hoboken, NJ: Wiley-Blackwell; 2021.